Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > MTX110
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(110)
•••
Comment by prophetoffactzon Dec 19, 2022 10:23pm
98 Views
Post# 35181277

RE:RE:RE:RE: MTX110

RE:RE:RE:RE: MTX110 An early-stage licensing model may be particularly unsustainable in a high inflation environment. No one really cares about revenue 7-10 years out given the inflation rate and the clinical risk and cash burn to get there. You don't make much licensing early to pharma. The burn rate quickly eats it up. 25% of biotech has has traded below the value of cash in recent months. No one cares.

BTI and Midatech are trying to escape that model and adapt to reality. They are convinced about the value of their assets and want to run with it. They believe they have game on their own! With the lead clinical assets a revenue ramp that sustains the company and a broad pipeline can be built. Hard data milestones are near. Early-stage licensing can complement on the way. Combing the two companies creates scale. Fast-track assets help bring revenue early. Small trials limit the upfront cash costs when cashburn is costly. BTI has waited a decade for others to move on their timeline and in secret. Enough already. This is the breaking point. Just do it!

@twhitfill
Nearly a quarter of all public biotech companies are trading below cash

Image
Image

Image
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities